Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Investigating dopaminergic neuronal vulnerability in Parkinson's Disease

EF 2025-26

Résumé
Parkinson's Disease (PD), the second most common neurodegenerative disorder worldwide, is characterized by the selective loss of dopaminergic (DA) neurons located in the substantia nigra region of the brain, leading to symptoms such as motor dysfunction, cognitive decline, and mood disorders. We have recently identified a sub-population of DA neurons marked by SOX6+/AGTR1+ that are more vulnerable to degeneration compared to other more resilient DA neuron populations. To design effective therapies to treat PD, this vulnerable population must be well-represented in our cell models to be able to identify key differences between vulnerable and resilient DA neurons. Astrocytes, non-neuronal cells of the brain that offer metabolic support and promote neuronal development, have also displayed disrupted signaling in PD and may affect the ratio of vulnerable and resilient DA neurons. My goal is to model human neuron-astrocyte interactions in PD in a dish, which I will use to identify genes involved in neuron resilience. Human induced pluripotent stem cells, obtained from skin or blood cells collected from patients, will be differentiated into dopaminergic neurons and astrocytes in a co-culture system. I will then use CRISPR technology to perform a screen to test which genes are involved in DA neuron resilience and examine how knockdown of these genes impacts DA neuron response to misfolded a-synuclein, which is implicated in PD progression. The genes identified in this screen will then be validated in cell villages, multi-donor cell models composed of neurons pooled from multiple PD patients and healthy controls, enabling us to capture and link the genetic diversity of many individuals to neuronal resilience and their differential responses to a-synuclein. The development of a system that captures the inherent dopaminergic neuronal vulnerability in Parkinson's Disease paves the way for therapeutic strategies to improve neuronal resilience and slow disease progression.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537131
Name
Ho Margaret T
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Investigating dopaminergic neuronal vulnerability in Parkinson's Disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Astrocyte-Neuron Interactions; Cell Villages; Dopaminergic Neurons; Neuronal Vulnerability; Parkinson'S Disease; Single Cell Rna-Sequencing
Abstract
Parkinson's Disease (PD), the second most common neurodegenerative disorder worldwide, is characterized by the selective loss of dopaminergic (DA) neurons located in the substantia nigra region of the brain, leading to symptoms such as motor dysfunction, cognitive decline, and mood disorders. We have recently identified a sub-population of DA neurons marked by SOX6+/AGTR1+ that are more vulnerable to degeneration compared to other more resilient DA neuron populations. To design effective therapies to treat PD, this vulnerable population must be well-represented in our cell models to be able to identify key differences between vulnerable and resilient DA neurons. Astrocytes, non-neuronal cells of the brain that offer metabolic support and promote neuronal development, have also displayed disrupted signaling in PD and may affect the ratio of vulnerable and resilient DA neurons. My goal is to model human neuron-astrocyte interactions in PD in a dish, which I will use to identify genes involved in neuron resilience. Human induced pluripotent stem cells, obtained from skin or blood cells collected from patients, will be differentiated into dopaminergic neurons and astrocytes in a co-culture system. I will then use CRISPR technology to perform a screen to test which genes are involved in DA neuron resilience and examine how knockdown of these genes impacts DA neuron response to misfolded a-synuclein, which is implicated in PD progression. The genes identified in this screen will then be validated in cell villages, multi-donor cell models composed of neurons pooled from multiple PD patients and healthy controls, enabling us to capture and link the genetic diversity of many individuals to neuronal resilience and their differential responses to a-synuclein. The development of a system that captures the inherent dopaminergic neuronal vulnerability in Parkinson's Disease paves the way for therapeutic strategies to improve neuronal resilience and slow disease progression.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ho, Margaret T
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~